AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 36164334
Drug: Ivermectin nanosuspension
RxNorm normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ivermectin nanosuspension mucoadhesive nasal spray (two puffs per day)
Trial: 36164935
Drug: Trastuzumab deruxtecan
RxNorm normalized name: Trastuzumab deruxtecan
DrugBank: Trastuzumab deruxtecan (DB14962)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Trastuzumab deruxtecan (T-DXd) at 6.4 mg/kg administered intravenously on day 1 of each 21-day cycle
Trial: 36165055
Drug: Mesalazine (Pentasa)
RxNorm normalized name: Mesalamine
DrugBank: Mesalazine (DB00244)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mesalazine (Pentasa) treatment
Trial: 36165893
Drug: FAK inhibition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FAK inhibition (defactinib) in combination with stereotactic body radiotherapy (RT)
Trial: 36165893
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of RT and FAK inhibition with checkpoint immunotherapy
Trial: 36166287
Drug: Care ally-assisted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Care ally-assisted massage (3.5-hour training workshop, instructional DVD, printed treatment manual, three 30-minute at-home sessions weekly for 3 months)
Trial: 36166287
Drug: Therapist-treated massage
RxNorm normalized name: trimethylsilyl treated diimethiconol-trimethylsiloxysilicate crosspolymer (45-55 WW)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapist-treated massage (two 60-minute sessions tailored to individual pain experiences and treatments per week for 3 months)
Trial: 36166340
Drug: Direct oral
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Direct oral anticoagulants (DOAC) with dual or triple antiplatelet therapy
Trial: 36166340
Drug: Vitamin K
RxNorm normalized name: Vitamin K
DrugBank: Phylloquinone (DB01022)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin K antagonists (warfarin) with corresponding strategies
Trial: 36166340
Drug: Dual antithrombotic
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual antithrombotic therapy
Trial: 36166648
Drug: Artificial intelligence-driven
RxNorm normalized name: Intelence
DrugBank: Etravirine (DB06414)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Artificial intelligence-driven digital health solution for self-management and clinical decision support
Trial: 36167584
Drug: Interprofessional medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interprofessional medication adherence intervention led by pharmacists, combining motivational interviews and feedback with electronic monitor (EM) drug assessment.
Trial: 36167894
Drug: High-dose cytarabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose cytarabine (HiDAC) with median dosage of 17.6 g/m (IQR 16.5-18.0)
Trial: 36167894
Drug: Intermediate-dose cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intermediate-dose cytarabine (IDAC)
Trial: 39141673
Drug: Inhaled Nitric
RxNorm normalized name: nitric oxide Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled Nitric Oxide
Trial: 36169998
Drug: Gameplay data
RxNorm normalized name: NO DATA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gameplay data analysis using state-of-the-art ML algorithms
Trial: 36170017
Drug: Early intensified
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early intensified treatment
Trial: 36170501
Drug: GPRC5D-targeted CAR
RxNorm normalized name: Autologous bi-epitope BCMA-targeted CAR T-cells
DrugBank: Ciltacabtagene autoleucel (DB16738)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GPRC5D-targeted CAR T-cell therapy (MCARH109) at a maximum tolerated dose of 150×10^6 cells.
Trial: 36170815
Drug: NADPH oxidase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NADPH oxidase inhibitor apocynin
Trial: 36171508
Drug: Low SVCF
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low SVCF < 55 ml/kg/min
Trial: 36171508
Drug: Combined use
RxNorm normalized name: CORTICOSTEROIDS FOR SYSTEMIC USE, COMBINATIONS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined use of low SVCF < 55 ml/kg/min and ACA-RI > 0.75
Trial: 36171508
Drug: Combined metrics
RxNorm normalized name: Polistes metricus venom protein
DrugBank: Polistes metricus venom protein (DB11029)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined metrics using cut-off value of < 41 ml/kg/min for SVCF and > 0.85 for ACA-RI
Trial: 36172030
Drug: Intravenous thrombolysis
RxNorm normalized name: thrombocytin
DrugBank: Serotonin (DB08839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous thrombolysis (IVT) with alteplase
Trial: 36172138
Drug: Infliximab (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infliximab (single dose infusion)
Trial: 36172517
Drug: Swedish quality
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Swedish quality register for systematic data collection from patients receiving treatment for gambling disorder.
Trial: 36172964
Drug: Spironolactone prescription
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Spironolactone prescription in ideal patients
Trial: 36172964
Drug: Spironolactone prescription
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Spironolactone prescription in contraindicated patients
Trial: 36175821
Drug: 1% atropine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% atropine weekly tapered to 0.01% atropine daily at 6 months
Trial: 36175821
Drug: 0.01% atropine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.01% atropine daily for 1 year
Trial: 36175948
Drug: Broad-spectrum antimicrobial
RxNorm normalized name: Sentinel Spectrum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Broad-spectrum antimicrobial therapy for more than 72 hours
Trial: 36175948
Drug: Narrow-spectrum antimicrobial
RxNorm normalized name: Sentinel Spectrum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Narrow-spectrum antimicrobial therapy (less than 72 hours)
Trial: 36178485
Drug: PCSK9i receivers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCSK9i receivers (ongoing treatment with evolocumab 140 mg, n=632, 38.1% of total)
Trial: 36178485
Drug: PCSK9i receivers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCSK9i receivers (ongoing treatment)
Trial: 36178583
Drug: Etanercept treatment
RxNorm normalized name: Etanercept
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Etanercept treatment adherence after 1 year
Trial: 36178583
Drug: Etanercept treatment
RxNorm normalized name: Etanercept
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Etanercept treatment adherence after 7 years
Trial: 36179090
Drug: Wearable sensors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wearable sensors during 1 week of unsupervised daily-living monitoring
Trial: 36179090
Drug: In-home off-medication
RxNorm normalized name: Off! Explore
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In-home off-medication testing
Trial: 36179090
Drug: In-home on-medication
RxNorm normalized name: selenium sulfide
DrugBank: Selenium Sulfide (DB00971)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In-home on-medication testing
Trial: 36179488
Drug: Dose and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose and volume de-escalated intensity-modulated radiation therapy (IMRT) after two cycles of induction chemotherapy with docetaxel 60 mg/m².
Trial: 36179736
Drug: Oral fexinidazole
RxNorm normalized name: fexinidazole
DrugBank: Fexinidazole (DB12265)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral fexinidazole (1200 mg for 20-34 kg; 1800 mg for 35 kg or more) once per day for 4 days, followed by 600 mg or 1200 mg once per day for 6 days.
Trial: 36180114
Drug: Self-administered questionnaires
RxNorm normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Self-administered questionnaires for sleep disorders
Trial: 36180329
Drug: Ixazomib monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ixazomib monotherapy
Trial: 36180329
Drug: Both treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatment groups (ixazomib monotherapy and ixazomib plus rituximab)
Trial: 36180844
Drug: Machine Learning
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Machine Learning (ML) algorithms for classification
Trial: 36181587
Drug: Cognitive Processing
RxNorm normalized name: Allogeneic processed thymus tissue
DrugBank: Allogeneic processed thymus tissue (DB16736)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Processing Therapy group (CPT)
Trial: 36182027
Drug: Brief Behavioral
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Brief Behavioral Therapy for Insomnia (BBTI)
Trial: 36182805
Drug: Proxalutamide 200
RxNorm normalized name: Proxalutamide
DrugBank: Proxalutamide (DB16065)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proxalutamide 200 mg/day
Trial: 36182805
Drug: Proxalutamide 200
RxNorm normalized name: Proxalutamide
DrugBank: Proxalutamide (DB16065)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proxalutamide 200 mg/day in triple-negative subgroup
Trial: 36183100
Drug: Monthly screening
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Monthly screening using ultrasensitive rapid diagnostic tests and treatment with dihydroartemisinin-piperaquine (DHA-PQ)
Trial: 36183444
Drug: Arfolitixorin (30,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arfolitixorin (30, 60, 120, or 240 mg/m) combined with 5-fluorouracil (5-FU)
Trial: 36183869
Drug: Access to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Access to antibody testing
Trial: 36184067
Drug: Lorlatinib (detailed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lorlatinib (detailed dosage and duration not specified)
Trial: 36184642
Drug: Camrelizumab 200
RxNorm normalized name: Ocrelizumab
DrugBank: Ocrelizumab (DB11988)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Camrelizumab 200 mg + Apatinib 500 mg + Fuzuloparib 100 mg
Trial: 36185311
Drug: Nanotechnology-enhanced immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nanotechnology-enhanced immunotherapy combined with ferroptosis; specific dosage and duration not mentioned.
Trial: 36185706
Drug: Intravenous difelikefalin
RxNorm normalized name: difelikefalin
DrugBank: Difelikefalin (DB11938)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous difelikefalin 0.5 μg/kg after each hemodialysis session for 12 weeks
Trial: 36185969
Drug: Homologous vaccination
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Homologous vaccination (three doses of BNT162b2) followed by BNT162b2 booster
Trial: 36185969
Drug: Heterologous vaccination
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heterologous vaccination (two doses of CoronaVac followed by BNT162b2 booster)
Trial: 36186648
Drug: BNT162b2 mRNA
RxNorm normalized name: SARS-CoV-2 (COVID-19) vaccine, mRNA-BNT162b2 Injectable Suspension [Comirnaty]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BNT162b2 mRNA vaccine administration to convalescent mothers
Trial: 36186721
Drug: Riociguat (0.5-2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Riociguat (0.5-2.5 mg three times daily, based on bodyweight)
Trial: 36186794
Drug: Tidal volume
RxNorm normalized name: VOLUME EXPANDERS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tidal volume of 6 mL/kg
Trial: 36186794
Drug: Tidal volume
RxNorm normalized name: VOLUME EXPANDERS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tidal volume of 8 mL/kg
Trial: 36186794
Drug: Tidal volume
RxNorm normalized name: VOLUME EXPANDERS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tidal volume of 10 mL/kg
Trial: 36186794
Drug: Tidal volume
RxNorm normalized name: VOLUME EXPANDERS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tidal volume of 12 mL/kg
Trial: 36186810
Drug: Topical lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical lidocaine ointment applied twice daily for 2 weeks
Trial: 36186856
Drug: Mindfulness-based group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mindfulness-based group therapy (Feel-Good intervention), 8 sessions over 8 weeks.
Trial: 36186962
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of IASBPD and PVR-derived parameters
Trial: 36188406
Drug: DHA +
RxNorm normalized name: PNV-DHA + Docusate Softgel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHA + EPA supplementation (2.442 g/day DHA and 1.020 g/day EPA)
Trial: 36188867
Drug: Repetitive Transcranial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repetitive Transcranial Magnetic Stimulation (rTMS) combined with Video Game-Based Training, details on dosage and duration not available
Trial: 36188946
Drug: Functional Electrical
RxNorm normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Functional Electrical Stimulation (FES) therapy delivered by the MyndMove stimulator, 40 sessions
Trial: 36189149
Drug: 0.5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg/kg hydroxyzine plus 0.5 mg/kg midazolam
Trial: 36189149
Drug: 1 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg/kg hydroxyzine plus 0.5 mg/kg midazolam
Trial: 36189149
Drug: 0.5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg/kg midazolam alone
Trial: 36189908
Drug: Primary dental
RxNorm normalized name: Sodium primary phosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Primary dental care (PDC) treatment
Trial: 36190737
Drug: Oral paracetamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral paracetamol 1000 mg × 4 + oral ibuprofen 400 mg × 4 + intravenous placebo
Trial: 36190737
Drug: Oral paracetamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral paracetamol 1000 mg × 4 + intravenous dexamethasone 24 mg + oral placebo
Trial: 36190737
Drug: Oral ibuprofen
RxNorm normalized name: ibuprofen Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ibuprofen 400 mg × 4 + intravenous dexamethasone 24 mg + oral placebo
Trial: 36190737
Drug: Oral paracetamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral paracetamol 1000 mg × 4 + oral ibuprofen 400 mg × 4 + intravenous dexamethasone 24 mg
Trial: 36190744
Drug: Chronolife smart
RxNorm normalized name: benzalkonium chloride Topical Foam [Smart San]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chronolife smart t-shirt worn daily for 2 weeks (preferably 8 hours per day)
Trial: 36190739
Drug: H2 antagonists
RxNorm normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: H2 antagonists (nizatidine, famotidine, ranitidine)
Trial: 36190739
Drug: Monoamine modulators
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monoamine modulators (reboxetine, fluoxetine)
Trial: 36190739
Drug: Placebo or
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo or no treatment (standard care)
Trial: 36192231
Drug: Ovulation Induction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ovulation Induction (OI) or No Treatment
Trial: 36192514
Drug: Combination intra-peritoneal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination intra-peritoneal and systemic chemotherapy
Trial: 36194670
Drug: Camrelizumab (CC)
RxNorm normalized name: Ocrelizumab
DrugBank: Camrelizumab (DB14776)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Camrelizumab (CC)
Trial: 36194670
Drug: Chemotherapy (CA)
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (CA)
Trial: 36194864
Drug: Low-dose multiplayer
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose multiplayer virtual reality telegaming program (2 supervised 1-hour sessions per week for 1 month)
Trial: 36195441
Drug: Intravenous infliximab
RxNorm normalized name: Infliximab
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravenous infliximab (IFX) 3 mg/kg
Trial: 36195441
Drug: Intravenous infliximab
RxNorm normalized name: Infliximab
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravenous infliximab (IFX)
Trial: 36196060
Drug: Time-to-diuretics (intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Time-to-diuretics (intravenous furosemide) administered within the first 24 hours, median time 67 minutes (25th-75th percentiles 17-190 minutes)
Trial: 36196060
Drug: Time-to-diuretics administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Time-to-diuretics administered between hospital arrival and 8 hours post-hospital arrival
Trial: 36196777
Drug: Fenfluramine (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenfluramine (0.2 mg/kg/day, titrated by effectiveness and tolerability)
Trial: 36196899
Drug: Nebulized morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulized morphine (nMOR) 10 mg
Trial: 36197661
Drug: Apremilast 30
RxNorm normalized name: apremilast 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apremilast 30 mg orally twice daily
Trial: 36197706
Drug: Bolstered usual
RxNorm normalized name: HYDROGEN PEROXIDE 5 mg in 100 mL TOPICAL LIQUID [USUALKLENZ DISINFECTANTSPRAY]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolstered usual care (literature on antiretroviral therapy adherence promotion and stigma reduction)
Trial: 36198179
Drug: IVIG (2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IVIG (2.0 g/kg every 4 weeks for 16 weeks)
Trial: 36198471
Drug: Machine learning
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Machine learning (ML) algorithm for reading WB-MRI scans
Trial: 36198471
Drug: ML-assisted reading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ML-assisted reading
Trial: 36198471
Drug: Experienced readers
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Experienced readers with ML
Trial: 36198471
Drug: Experienced readers
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Experienced readers without ML
Trial: 36198701
Drug: Non-invasive spinal
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-invasive spinal neuromodulation during activity-based neurorehabilitation therapy (ABNT), 2x/week for 8 weeks
Trial: 36198701
Drug: Activity-based neurorehabilitation
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Activity-based neurorehabilitation therapy (ABNT) alone
Trial: 36200380
Drug: Frontline treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Frontline treatment for Hodgkin lymphoma
Trial: 36200417
Drug: Tucidinostat 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tucidinostat 40 mg twice per week (BIW)
Trial: 36200668
Drug: Spartalizumab monotherapy
RxNorm normalized name: Natalizumab
DrugBank: Natalizumab (DB00108)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Spartalizumab monotherapy
Trial: 36200701
Drug: Nirmatrelvir/ritonavir treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nirmatrelvir/ritonavir treatment
Trial: 36201124
Drug: Treatment with
RxNorm normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment with glucocorticoids
Trial: 36201124
Drug: Treatment with
RxNorm normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment with rituximab
Trial: 36201545
Drug: Fluoroquinolones and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoroquinolones and other antibiotics (post-hoc analysis excluding ophthalmic drops)
Trial: 36201545
Drug: Oral Fluoroquinolones
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Fluoroquinolones
Trial: 36203544
Drug: Abatacept (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abatacept (10 mg/kg, maximum dose 1000 mg) plus standard of care (SOC)
Trial: 36203563
Drug: BNT162b2 (0.3ml
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BNT162b2 (0.3ml intramuscular, homologous)
Trial: 36203563
Drug: CoronaVac (0.5ml
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CoronaVac (0.5ml intramuscular, homologous)
Trial: 36203563
Drug: CoronaVac (0.5ml
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CoronaVac (0.5ml intradermal)
Trial: 36203563
Drug: BNT162b2 (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BNT162b2 (2 doses intramuscular, 1 dose intradermal)
Trial: 36203760
Drug: Portable sauna
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Portable sauna bath (30-min, 45°C sauna bath, daily for 10 days)
Trial: 36203975
Drug: 0.65 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.65 mg/kg r-tPA
Trial: 36203975
Drug: 0.90 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.90 mg/kg r-tPA